These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 1979168)
1. Tissue-specific transformation by epidermal growth factor receptor: a single point mutation within the ATP-binding pocket of the erbB product increases its intrinsic kinase activity and activates its sarcomagenic potential. Shu HK; Pelley RJ; Kung HJ Proc Natl Acad Sci U S A; 1990 Dec; 87(23):9103-7. PubMed ID: 1979168 [TBL] [Abstract][Full Text] [Related]
2. Modulation of erbB kinase activity and oncogenic potential by single point mutations in the glycine loop of the catalytic domain. Shu HK; Chang CM; Ravi L; Ling L; Castellano CM; Walter E; Pelley RJ; Kung HJ Mol Cell Biol; 1994 Oct; 14(10):6868-78. PubMed ID: 7935404 [TBL] [Abstract][Full Text] [Related]
3. Dissecting the activating mutations in v-erbB of avian erythroblastosis virus strain R. Shu HK; Pelley RJ; Kung HJ J Virol; 1991 Nov; 65(11):6173-80. PubMed ID: 1681117 [TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase activity may be necessary but is not sufficient for c-erbB1-mediated tissue-specific tumorigenicity. Connolly DC; Toutenhoofd SL; Maihle NJ J Virol; 1994 Oct; 68(10):6804-10. PubMed ID: 7916062 [TBL] [Abstract][Full Text] [Related]
5. Disease tropism of c-erbB: effects of carboxyl-terminal tyrosine and internal mutations on tissue-specific transformation. Pelley RJ; Maihle NJ; Boerkoel C; Shu HK; Carter TH; Moscovici C; Kung HJ Proc Natl Acad Sci U S A; 1989 Sep; 86(18):7164-8. PubMed ID: 2550929 [TBL] [Abstract][Full Text] [Related]
6. Native avian c-erbB gene expresses a secreted protein product corresponding to the ligand-binding domain of the receptor. Maihle NJ; Flickinger TW; Raines MA; Sanders ML; Kung HJ Proc Natl Acad Sci U S A; 1991 Mar; 88(5):1825-9. PubMed ID: 1672045 [TBL] [Abstract][Full Text] [Related]
7. An oncogenic point mutation confers high affinity ligand binding to the neu receptor. Implications for the generation of site heterogeneity. Ben-Levy R; Peles E; Goldman-Michael R; Yarden Y J Biol Chem; 1992 Aug; 267(24):17304-13. PubMed ID: 1355090 [TBL] [Abstract][Full Text] [Related]
8. Biochemical comparisons of the normal and oncogenic forms of insect cell-expressed neu tyrosine kinases. Guy PM; Carraway KL; Cerione RA J Biol Chem; 1992 Jul; 267(20):13851-6. PubMed ID: 1352772 [TBL] [Abstract][Full Text] [Related]
9. The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain. Akiyama T; Matsuda S; Namba Y; Saito T; Toyoshima K; Yamamoto T Mol Cell Biol; 1991 Feb; 11(2):833-42. PubMed ID: 1671296 [TBL] [Abstract][Full Text] [Related]
10. The multiple endocrine neoplasia type 2B point mutation alters long-term regulation and enhances the transforming capacity of the epidermal growth factor receptor. Pandit SD; Donis-Keller H; Iwamoto T; Tomich JM; Pike LJ J Biol Chem; 1996 Mar; 271(10):5850-8. PubMed ID: 8621456 [TBL] [Abstract][Full Text] [Related]
11. A minor tyrosine phosphorylation site located within the CAIN domain plays a critical role in regulating tissue-specific transformation by erbB kinase. Chang CM; Shu HK; Ravi L; Pelley RJ; Shu H; Kung HJ J Virol; 1995 Feb; 69(2):1172-80. PubMed ID: 7815495 [TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of three erbB transducing viruses generated during avian leukosis virus-induced erythroleukemia: extensive internal deletion near the kinase domain activates the fibrosarcoma- and hemangioma-inducing potentials of erbB. Raines MA; Maihle NJ; Moscovici C; Moscovici MG; Kung HJ J Virol; 1988 Jul; 62(7):2444-52. PubMed ID: 2836624 [TBL] [Abstract][Full Text] [Related]
13. The erbB gene and the EGF receptor. Martin GS Cancer Surv; 1986; 5(2):199-219. PubMed ID: 2877733 [TBL] [Abstract][Full Text] [Related]
14. Activation of the proto-oncogene p60c-src by point mutations in the SH2 domain. O'Brien MC; Fukui Y; Hanafusa H Mol Cell Biol; 1990 Jun; 10(6):2855-62. PubMed ID: 2111444 [TBL] [Abstract][Full Text] [Related]
15. NIH/3T3 cells transformed with the activated erbB-2 oncogene can be phenotypically reverted by a kinase deficient, dominant negative erbB-2 variant. Messerle K; Schlegel J; Hynes NE; Groner B Mol Cell Endocrinol; 1994 Oct; 105(1):1-10. PubMed ID: 7821711 [TBL] [Abstract][Full Text] [Related]
16. The carboxy-terminal domains of erbB-2 and epidermal growth factor receptor exert different regulatory effects on intrinsic receptor tyrosine kinase function and transforming activity. Di Fiore PP; Segatto O; Lonardo F; Fazioli F; Pierce JH; Aaronson SA Mol Cell Biol; 1990 Jun; 10(6):2749-56. PubMed ID: 2188097 [TBL] [Abstract][Full Text] [Related]
17. A chimeric EGF-R-neu proto-oncogene allows EGF to regulate neu tyrosine kinase and cell transformation. Lehväslaiho H; Lehtola L; Sistonen L; Alitalo K EMBO J; 1989 Jan; 8(1):159-66. PubMed ID: 2565807 [TBL] [Abstract][Full Text] [Related]
18. A point mutation at tyrosine-809 in the human colony-stimulating factor 1 receptor impairs mitogenesis without abrogating tyrosine kinase activity, association with phosphatidylinositol 3-kinase, or induction of c-fos and junB genes. Roussel MF; Shurtleff SA; Downing JR; Sherr CJ Proc Natl Acad Sci U S A; 1990 Sep; 87(17):6738-42. PubMed ID: 2168557 [TBL] [Abstract][Full Text] [Related]
19. Deletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor function. Humphrey PA; Gangarosa LM; Wong AJ; Archer GE; Lund-Johansen M; Bjerkvig R; Laerum OD; Friedman HS; Bigner DD Biochem Biophys Res Commun; 1991 Aug; 178(3):1413-20. PubMed ID: 1678600 [TBL] [Abstract][Full Text] [Related]
20. Demonstration of ligand-dependent signaling by the erbB-3 tyrosine kinase and its constitutive activation in human breast tumor cells. Kraus MH; Fedi P; Starks V; Muraro R; Aaronson SA Proc Natl Acad Sci U S A; 1993 Apr; 90(7):2900-4. PubMed ID: 8464905 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]